Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Just The Tonix: New York Biotech Has Breakthrough Drug For PTSD
Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues
Clovis Transitions To Commercial Stage On Rubraca Approval
Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?
ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno
Nearing Finish Line, HCV Race Focuses On Salvage Therapy
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts